BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28

• 

  Government

  Trump’s Whiplash Policies Keep Pharmas on Their Toes

  As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives find themselves faced with policy questions ranging from the Inflation Reduction Act to RFK Jr.

  February 12, 2025

   · 

  4 min read

   · 

  Annalee Armstrong
• 

  Infectious disease

  Anticipating Approval, Gilead Gears Up for Mid-Year Launch for Lenacapavir PrEP

  Gilead beat consensus estimates in Q4 with $7.6 billion in revenue, driven largely by its HIV drug Biktarvy and CAR T therapies Trodelvy and Yescarta.

  February 12, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  AbbVie Triples Down on T Cell Therapies in Xilio Deal Worth Up to $2.1B

  The pharma giant inked its third T cell engager deal of 2025 Wednesday—this time with Xilio Therapeutics for tumor-activated immunotherapies.

  February 12, 2025

   · 

  1 min read

   · 

  Kate Goodwin
• 

  Job Trends

  2024 Q4 Job Market Report: Biopharma Job Postings Slowed as Layoffs Continued

  Year-over-year BioSpace data show there were fewer job postings live on the website in the fourth quarter of 2024, and the decrease was higher than the third quarter’s drop.

  February 12, 2025

   · 

  3 min read

   · 

  Angela Gabriel
• 

  Collaboration

  Incyte Backs Out of Immuno-Oncology Pact With Agenus

  The partnership dates back to 2015, when Incyte paid $60 million upfront for access to four checkpoint programs, including TIM-3, LAG-3, OX40 and GITR.

  February 12, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Collaboration

  Biogen Taps Royalty Pharma for $250M to Power Phase III Lupus Program

  The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the company’s forecasted dip in 2025 revenues.

  February 12, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Leadership

  Vir Leans Into Immunology Roots After Flamed-Out COVID Fame

  Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer stepped in as CEO to answer a critical question: What’s next?

  February 12, 2025

   · 

  5 min read

   · 

  Annalee Armstrong
• 

  Earnings

  With Leqembi Sales Trending Up, Biogen Gets Down to Brass Tacks: It Works

  Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s disease. With patients now hitting the 18-month mark of treatment, the conversation is finally shifting to efficacy.

  February 12, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  GLP-1

  Lilly, Novo Skew Overall Pharma Trends With Colossal GLP-1 Sales Growth

  From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved into a new pharma stratosphere, far eclipsing their rivals.

  February 12, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Podcast

  New M&A Action, BMS’ Ongoing Cost Cuts and the Insatiable Demand for Weight Loss Drugs

  Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, sales continue to soar for Lilly and Novo Nordisk’s GLP-1s and Regeneron sues Sanofi over an alleged failure to provide adequate information about Dupixent sales.

  February 12, 2025

   · 

  1 min read

   · 

  Heather McKenzie